Peptide Initiative

Peptides · Peptide comparison

Chonluten vs LL-37

Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue

Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeChonluten5–10 mgLL-371.6–1.6 mg/mL
FrequencyChonlutenOnce dailyLL-37Once daily
AdministrationChonlutenSublingual (enteric-coated capsules)LL-37Topical application (wound healing)
Cycle lengthChonluten12+ weeksLL-3712+ weeks
Onset speedChonlutenGradual (3-4 weeks)LL-37Moderate (1-2 weeks)
Evidence levelChonlutenLimited human trialsLL-37Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Respiratory Tissue Repair

Chonluten62%
LL-37No recorded rating

Lung Inflammation Control

Chonluten58%
LL-37No recorded rating

Age-Related Lung Protection

Chonluten55%
LL-37No recorded rating

Wound Healing

ChonlutenNo recorded rating
LL-3794%

Fighting Infections

ChonlutenNo recorded rating
LL-3791%

Immune Boost

ChonlutenNo recorded rating
LL-3787%

Technical data

Compound specifications

Chonluten

Molecular formula
C11H17N3O8
Molecular weight
319.27 g/mol
Half-life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
CAS number
75007-24-8

LL-37

Molecular formula
C205H340N60O53
Molecular weight
4,493.26 Da
Half-life
Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
Bioavailability
Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
CAS number
154947-66-7

Protocols

Dosing compared

Chonluten

Subcutaneous

  • 5-10 mgOnce daily · 10-20 days per courseFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]

Oral

  • 1-2 capsules1-2 times daily with meals · 10-30 day course, repeated 2-3 times per yearThe oral capsule plan used in practice for this bronchopulmonary peptide supplement. [6]

LL-37

Topical

  • 0.5 mg/mL gelTwice weekly · 4 weeksLowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].
  • 1.6 mg/mL gelTwice weekly · 4 weeksMid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].

Applications

Best suited for

Chonluten

Respiratory health restoration in aging individuals with declining lung function
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic bronchopulmonary conditions requiring tissue-level regenerative support
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for lung tissue preservation in elderly populations
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

LL-37

Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][5].
Anti-biofilm strategies for chronic wound infections and medical device-associated infections
LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Boosting innate immune defense in immunocompromised or aging individuals
LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].

Safety profile

Side effects

Chonluten

Common

  • Injection site reaction
  • Mild fatigue
  • Transient respiratory changes
  • Mild headache

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

LL-37

Common

  • Local site irritation
  • Transient stinging or burning
  • Mild perilesional erythema
  • Increased wound exudate

Uncommon

  • Allergic contact reaction

Serious

  • Hemolytic activity at systemic concentrations

Research status

Safety & evidence

Chonluten

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active pulmonary infections requiring immediate medical treatment
  • Severe immunosuppression without medical supervision — immunomodulatory effects may be unpredictable

LL-37

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, [2] conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

Contraindications

  • Known hypersensitivity to cathelicidin peptides or formulation components
  • Active hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
  • Pregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
  • Severe renal impairment — peptide clearance may be altered

Decision guide

Which is right for you?

Chonluten

Choose Chonluten if…

  • Respiratory health restoration in aging individuals with declining lung function
  • Chronic bronchopulmonary conditions requiring tissue-level regenerative support
  • Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
  • Geroprotective therapy for lung tissue preservation in elderly populations

LL-37

Choose LL-37 if…

  • Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
  • Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
  • Anti-biofilm strategies for chronic wound infections and medical device-associated infections
  • Boosting innate immune defense in immunocompromised or aging individuals